Eur J Cancer:来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗

2022-03-30 xiaozeng MedSci原创

来曲唑+帕博西尼新辅助治疗或可替代高危型雌激素受体阳性HER2阴性的乳腺癌女性患者的化疗。

除了作为额外的辅助治疗,CDK4/6 抑制剂联合内分泌疗法还可能是绝经后的高危型雌激素受体阳性、HER2阴性女性乳腺癌患者化疗的较低毒性替代方案。

2期的NEOPAL试验是一项多中心、国际性、随机化的临床研究,主要终点分析显示,上述患者采用来曲唑-帕博西尼联合方案治疗的临床和病理反应与蒽环类-紫杉类药物序贯化疗的相当。

本文报告了NEOPAL试验的次要终点,包括无进展生存期(PFS)和无侵袭性疾病生存期(iDFS)。此外,还有该试验的探索性终点,包括总生存期(OS)和乳腺癌特异性的生存率(BCSS)。

两组患者的无进展生存期(a)、无侵袭性疾病生存期(b)、乳腺癌特异性生存率(c)和总生存期(d)

在该试验中,共有106位患者被随机分至两组(各53位),接受了来曲唑-帕博西尼(实验组)治疗或化疗(对照组)。实验组和对照组的病理完全缓解率分别是3.8%和5.9%。实验组的53位患者中有23位接受了术后辅助化疗。中位随访了40.4个月后,共观察到了11例进展,其中3例在实验组,8例在对照组。两组间的PFS(HR 1.01, p=0.98)和iDFS(HR 0.83, p=0.71)均无显著差异。实验组和对照组的40个月PFS率分别是86.7%和89.9%。有无接受化疗的患者的预后在统计学上没有明显差异。

综上所述,NEOPAL研究表明,来曲唑-帕博西尼新辅助治疗方案有望使部分腔内乳腺癌患者免受化疗之苦,同时获得了一个较好的长期预后。

 

原始出处:

Delaloge Suzette,Dureau Sylvain,D'Hondt Véronique et al. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.[J] .Eur J Cancer, 2022, https://doi.org/10.1016/j.ejca.2022.01.014.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1678734, encodeId=5d7f16e87349f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Nov 26 01:03:25 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982553, encodeId=b34919825530b, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 29 18:03:25 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207358, encodeId=cb8c120e35801, content=学习一下哈~, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Mar 30 22:08:59 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207334, encodeId=2a9a120e3345d, content=我一个外行,图啥画的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48356166857, createdName=ms4000001152517425, createdTime=Wed Mar 30 21:13:30 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340428, encodeId=038c1340428e6, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492025, encodeId=bc87149202501, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1678734, encodeId=5d7f16e87349f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Nov 26 01:03:25 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982553, encodeId=b34919825530b, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 29 18:03:25 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207358, encodeId=cb8c120e35801, content=学习一下哈~, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Mar 30 22:08:59 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207334, encodeId=2a9a120e3345d, content=我一个外行,图啥画的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48356166857, createdName=ms4000001152517425, createdTime=Wed Mar 30 21:13:30 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340428, encodeId=038c1340428e6, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492025, encodeId=bc87149202501, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
    2022-07-29 luwei00
  3. [GetPortalCommentsPageByObjectIdResponse(id=1678734, encodeId=5d7f16e87349f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Nov 26 01:03:25 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982553, encodeId=b34919825530b, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 29 18:03:25 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207358, encodeId=cb8c120e35801, content=学习一下哈~, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Mar 30 22:08:59 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207334, encodeId=2a9a120e3345d, content=我一个外行,图啥画的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48356166857, createdName=ms4000001152517425, createdTime=Wed Mar 30 21:13:30 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340428, encodeId=038c1340428e6, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492025, encodeId=bc87149202501, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
    2022-03-30 xulv123

    学习一下哈~

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1678734, encodeId=5d7f16e87349f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Nov 26 01:03:25 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982553, encodeId=b34919825530b, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 29 18:03:25 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207358, encodeId=cb8c120e35801, content=学习一下哈~, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Mar 30 22:08:59 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207334, encodeId=2a9a120e3345d, content=我一个外行,图啥画的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48356166857, createdName=ms4000001152517425, createdTime=Wed Mar 30 21:13:30 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340428, encodeId=038c1340428e6, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492025, encodeId=bc87149202501, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
    2022-03-30 ms4000001152517425

    我一个外行,图啥画的?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1678734, encodeId=5d7f16e87349f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Nov 26 01:03:25 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982553, encodeId=b34919825530b, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 29 18:03:25 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207358, encodeId=cb8c120e35801, content=学习一下哈~, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Mar 30 22:08:59 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207334, encodeId=2a9a120e3345d, content=我一个外行,图啥画的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48356166857, createdName=ms4000001152517425, createdTime=Wed Mar 30 21:13:30 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340428, encodeId=038c1340428e6, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492025, encodeId=bc87149202501, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
    2022-03-29 siiner
  6. [GetPortalCommentsPageByObjectIdResponse(id=1678734, encodeId=5d7f16e87349f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Nov 26 01:03:25 CST 2022, time=2022-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982553, encodeId=b34919825530b, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 29 18:03:25 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207358, encodeId=cb8c120e35801, content=学习一下哈~, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Mar 30 22:08:59 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207334, encodeId=2a9a120e3345d, content=我一个外行,图啥画的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48356166857, createdName=ms4000001152517425, createdTime=Wed Mar 30 21:13:30 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340428, encodeId=038c1340428e6, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492025, encodeId=bc87149202501, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Tue Mar 29 12:03:25 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
    2022-03-29 nymo

相关资讯

年轻男性乳房发育症存在偶然病理发现,病检是否该作为常规检查?

对成年男性乳房发育症人群进行的大规模研究表明,偶发性病理学发现的发病率较低,但可明显提高乳腺癌的风险。鉴于该人群中乳腺癌的发病率较低,对年轻男性乳房组织的病理检查存在争议。

Eur J Cancer:卡培他滨辅助治疗对乳腺癌患者生存预后的影响

卡培他滨可改善三阴性乳腺癌患者的无病生存预后和总生存预后,加入系统治疗时还可改善所有早期乳腺癌患者的无病生存预后和总生存预后

Cancers:世界首创!小分子药物可抑制人类乳腺癌复发和转移

乳腺癌,是女性中最常见的癌症,在神刊 CA 2021年癌症统计报告中显示,乳腺癌已成为女性三大癌症之首,仅乳腺癌就占女性癌症的30%。而在中国,乳腺癌的发病率也在逐年提升。

这2项新型指数,不仅反映个人饮食炎症水平,得分高者乳腺癌发生风险升高超150%?

Nutr J:新型饮食和生活方式炎症指数与乳腺癌风险(BrCa)之间的关系:病例对照研究

良好的术前心理竟然可以减少乳房重建术后并发症

心理因素被广泛理解为有助于整体健康,但它们对伤口愈合的作用还没有很好地定义。术前身体形象等心理因素与术后并发症的相关性资料有限。

NEJM:Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌

对于接受过曲妥珠单抗联合紫杉醇治疗后出现疾病进展的HER2阳性转移性乳腺癌患者,接受Trastuzumab deruxtecan治疗在降低疾病进展或死亡风险方面优于Trastuzumab emtans